tirzepatide 30 mg Tirzepatide-RUO 30MG 30 mg tirzepatide Tirzepatide –

Patients receive the same active ingredient (semaglutide) as Ozempic but at a fraction of the pharmaceutical brand's markup

This includes an initial water weight drop in weeks 1 to 3, a common plateau at week 4, and steadier fat loss starting week 5 when the dose increases from 0.25mg to 0.5mg

This gradual titration minimizes gastrointestinal adverse effects

Clear baseline assessment before starting semaglutide helps distinguish medication effects from thyroid dysfunction

According to the SmPC and in line with NICE guidance (TA664), treatment should be discontinued if less than 5% of initial body weight is lost after 12 weeks on the maintenance dose of 3.0 mg daily